About: Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial
Creator	Prieschl-Grassauer, Eva Grassauer, Andreas Lion, Thomas Rauch, Margit Bodenteich, Angelika Enzenhofer, Elisabeth Ludwig, Martin Neumann, Kurt Schneider, Sven Mueller, Christian
Source	Medline; PMC
abstract	BACKGROUND: The common cold is the most widespread viral infection in humans. Iota-carrageenan has previously shown antiviral effectiveness against cold viruses in clinical trials. This study investigated the efficacy of a carrageenan-containing nasal spray on the duration of the common cold and nasal fluid viral load in adult patients. METHODS: In a randomized, double-blind, placebo-controlled trial, 211 patients suffering from early symptoms of the common cold were treated for seven days. Application was performed three times daily with either a carrageenan-supplemented nasal spray or saline solution as placebo with an overall observation period of 21 days. The primary endpoint was the duration of disease defined as the time until the last day with symptoms followed by all other days in the study period without symptoms. During the study, but prior unblinding, the definition of disease duration was adapted from the original protocol that defines disease duration as the time period of symptoms followed by 48 hours without symptoms. RESULTS: In patients showing a laboratory-confirmed cold virus infection and adherence to the protocol, alleviation of symptoms was 2.1 days faster in the carrageenan group in comparison to placebo (p = 0.037). The primary endpoint that had been prespecified but was changed before unblinding was not met. Viral titers in nasal fluids showed a significantly greater decrease in carrageenan patients in the intention-to-treat population (p = 0.024) and in the per protocol population (p = 0.018) between days 1 and 3/4. CONCLUSIONS: In adults with common cold virus infections, direct local administration of carrageenan with nasal sprays reduced the duration of cold symptoms. A significant reduction of viral load in the nasal wash fluids of patients confirmed similar findings from earlier trials in children and adults. TRIAL REGISTRATION: Current Controlled Trials ISRCTN80148028
has issue date	2013-11-13(xsd:dateTime)
bibo:doi	10.1186/1465-9921-14-124
bibo:pmid	24219370
has license	cc-by
sha1sum (hex)	92911175d25c9f4bce7ace3050a4ddea1f5105eb
schema:url	https://doi.org/10.1186/1465-9921-14-124
resource representing a document's title	Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial
has PubMed Central identifier	PMC3840586
has PubMed identifier	24219370
schema:publication	Respir Res
resource representing a document's body	covid:92911175d25c9f4bce7ace3050a4ddea1f5105eb#body_text
is schema:about of	named entity 'BUT' named entity 'DAY' named entity 'UNBLINDING' named entity 'SEVEN' named entity 'PLACEBO-CONTROLLED TRIAL' named entity 'SALINE SOLUTION' named entity 'EFFECTIVENESS' named entity 'ADAPTED' named entity 'VIRAL INFECTION' named entity 'ANTIVIRAL' named entity 'ORIGINAL' named entity 'PRIMARY ENDPOINT' named entity 'SUFFERING' named entity 'RANDOMIZED' named entity 'BLIND' named entity 'METHODS' named entity 'PATIENTS' named entity 'STUDY' named entity 'common cold' named entity 'RANDOMIZED CONTROLLED TRIAL' named entity 'ADULT' named entity 'EFFICACY' named entity 'DEFINITION' named entity 'TIME PERIOD' named entity 'INVESTIGATED' named entity 'PREVIOUSLY' named entity 'TIME' named entity 'EITHER' named entity 'DOUBLE' named entity 'PROTOCOL' named entity 'EARLY' named entity 'PRIOR' named entity 'DISEASE DURATION' named entity 'COLD' named entity 'CONTAINING' named entity 'VIRUSES' named entity 'COMMON COLD' named entity 'DAYS' named entity 'NASAL SPRAY' named entity 'CARRAGEENAN' named entity 'FOLLOWED BY' named entity 'PATIENTS' named entity 'CARRAGEENAN' named entity 'BACKGROUND' named entity 'THREE TIMES DAILY' named entity 'DEFINED' named entity 'WIDESPREAD' named entity 'CLINICAL TRIALS' named entity 'IOTA-CARRAGEENAN' named entity 'PERFORMED' named entity 'OBSERVATION' named entity 'APPLICATION' named entity 'NASAL FLUID' named entity 'OVERALL' named entity 'NASAL SPRAY' named entity 'COMMON COLD' named entity 'EFFICACY' named entity 'DURATION' named entity 'TREATED FOR' named entity 'PERIOD' named entity 'HUMANS' named entity 'DURATION OF DISEASE' named entity 'SYMPTOMS' named entity 'PLACEBO' named entity '48 HOURS' named entity 'VIRAL LOAD' covid:arg/92911175d25c9f4bce7ace3050a4ddea1f5105eb named entity 'original' named entity 'nasal spray' named entity 'period' named entity 'study' named entity 'The common'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software